The Conference Call on Q3 2026 takes place on November 3, 2026
CMS news on End Stage Renal Disease (ESRD) Prospective Payment System (PPS) for 2027
The U.S. Centers for Medicare & Medicaid Services (CMS) published the final rule on End Stage Renal Disease (ESRD) Prospective Payment System (PPS) for 2027 on their website:
Calendar Year (CY) 2027 End-Stage Renal Disease (ESRD) Prospective Payment System Proposed Rule | CMS
The final rule is largely in line with our expectations.
FME remains committed to working with CMS, U.S. Department of Health & Human Services, and stakeholders across the kidney care ecosystem to advance innovations including high-volume hemodiafiltration (HvHDF), expand patient choice, and improve access to therapies across the entire continuum of kidney care.
Selected data points from the CMS rule:
CMS final rule | 2027 (draft rule) |
ESRD PPS rate – base rate | $297.65 (draft rule: $299.55) |
Net Market Basket Update | +1.9% (draft rule: +1.1%) |
ESRD PPS rate – LDO | +3.5% (draft rule: +1.9%) |
Phosphate binders –rate increase included in ESRD PPS base rate above | $12.85 (draft rule: $15.96) |
DefenCath – add-on payment adjustment | + $8.3220 US$ (draft rule: + $5.5951 US$) |
Changes in percent are against prior year.
Please refer to the CMS website for the full set of details.
Related content
-
-
Fresenius Medical Care – THE RENAL COMPANY is the world’s leading provider of dialysis products and services. Find out more about the company’s history.
No Results Found